Vaxcyte Secures Major Funding, Advances Key Vaccine to Phase 3 Trials
Vaxcyte (PCVX) bolsters its financial position with a successful public offering, channeling fresh capital into pivotal late-stage trials for its broad-spectrum pneumococcal vaccine candidate, VAX-31, in both adults and infants.